Belite Bio, Inc
BLTE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $11 | $9 | $7 |
| G&A Expenses | $13 | $7 | $6 | $4 |
| SG&A Expenses | $13 | $7 | $6 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $23 | $18 | $16 | $11 |
| Operating Income | -$23 | -$18 | -$16 | -$11 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$22 | -$16 | -$14 | -$10 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$22 | -$16 | -$14 | -$10 |
| % Margin | – | – | – | – |
| EPS | -0.65 | -0.5 | -0.44 | -0.32 |
| % Growth | -30% | -13.6% | -37.5% | – |
| EPS Diluted | -0.65 | -0.5 | -0.44 | -0.32 |
| Weighted Avg Shares Out | 33 | 33 | 32 | 31 |
| Weighted Avg Shares Out Dil | 33 | 33 | 32 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$22 | -$16 | -$15 | -$8 |
| % Margin | – | – | – | – |